Today in Science
SEE OTHER BRANDS

Fresh science news from the world

Today in Science: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Today in Science.

Press releases published on May 29, 2025

New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes

New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes

FRIENDSWOOD, Texas, May 29, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will present novel research aimed at enhancing the clinical management of patients …

Blaize to Attend D.A. Davidson 1st Annual Consumer & Technology Conference

Blaize to Attend D.A. Davidson 1st Annual Consumer & Technology Conference

EL DORADO HILLS, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Blaize Holdings, Inc. (NASDAQ: BZAI), a pioneer in scalable, energy-efficient AI computing across edge to cloud, today announced it will participate in the upcoming D.A. Davidson 1st Annual Consumer …

RIB Software Launches Global Customer Campaign: “You See It. Together, We’ll See It Through”

RIB Software Launches Global Customer Campaign: “You See It. Together, We’ll See It Through”

Stuttgart, Germany, May 29, 2025 (GLOBE NEWSWIRE) -- Stuttgart, Germany – May 2025 – RIB Software, a global leader in engineering and construction software technology, today announced the launch of its latest global brand campaign: “You See It. Together, …

Alumis to Present at the Jefferies Global Healthcare Investor Conference

Alumis to Present at the Jefferies Global Healthcare Investor Conference

SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that Martin Babler, President …

Microchip Technology Raises Financial Guidance for Sales and EPS for First Quarter of Fiscal Year 2026

Microchip Technology Raises Financial Guidance for Sales and EPS for First Quarter of Fiscal Year 2026

CHANDLER, Ariz., May 29, 2025 (GLOBE NEWSWIRE) -- Microchip Technology Incorporated, a leading provider of smart, connected, and secure embedded control solutions, today updated the range of its prior guidance for net Sales and GAAP and non-GAAP earnings …

Fulcrum Therapeutics to Present at Upcoming Medical Meetings

Fulcrum Therapeutics to Present at Upcoming Medical Meetings

CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare …

Kevin Rubin Joins Zscaler as Chief Financial Officer to Drive Continued Growth

Kevin Rubin Joins Zscaler as Chief Financial Officer to Drive Continued Growth

SAN JOSE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Zscaler, Inc. (NASDAQ: ZS), the leader in cloud security, today announced the appointment of Kevin Rubin as Chief Financial Officer. In his role, Rubin will oversee Zscaler’s global finance organization …

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June

CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today …

NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025

NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025

LNCB74 is in a Phase 1, open-label, first-in-human study that will include dose escalation, safety, and biomarker backfills and randomized dose expansion/optimization The study is currently enrolling in dose escalation Poster to be presented June 2, 2025, …

Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025

Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025

SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that members …

AGM Group Holdings Inc. Announces Effective Date of 50 for 1 Share Consolidation

AGM Group Holdings Inc. Announces Effective Date of 50 for 1 Share Consolidation

Beijing, May 29, 2025 (GLOBE NEWSWIRE) -- AGM Group Holdings Inc. (“AGM Holdings” or the “Company”) (NASDAQ: AGMH), an integrated technology company specializing in the assembling and sales of high-performance hardware and computing equipment, today …

Amneal to Participate at Upcoming Investor Conferences in June

Amneal to Participate at Upcoming Investor Conferences in June

BRIDGEWATER, N.J., May 29, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) will participate in two upcoming investor conferences: Jefferies Global Healthcare Conference on June 5, 2025, with company presentation at 9:20 AM ET, and …

Annexon Biosciences to Present at the Jefferies Global Healthcare Conference

Annexon Biosciences to Present at the Jefferies Global Healthcare Conference

BRISBANE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory …

Zscaler Reports Third Quarter Fiscal 2025 Financial Results

Zscaler Reports Third Quarter Fiscal 2025 Financial Results

Third Quarter Highlights Revenue grows 23% year-over-year to $678.0 million Calculated billings grows 25% year-over-year to $784.5 million Deferred revenue grows 26% year-over-year to $1,985.0 million GAAP net loss of $4.1 million compared to GAAP net …

Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences

Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences

FOSTER CITY, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, …

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

SAN FRANCISCO, May 29, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced that management will …

Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) For Extended-Release Oral Suspension at SLEEP 2025

Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) For Extended-Release Oral Suspension at SLEEP 2025

– 14 abstracts accepted, including four oral presentations – – Interim analysis of real-world REFRESH study demonstrated clinically significant efficacy and improvement of EDS for patients who switched from twice-nightly oxybate to once-at-bedtime LUMRYZ – …

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

LONDON, May 29, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will present at the following investor conferences in June: Jefferies 2025 Global Healthcare Conference on Thursday, June 5 …

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) …

Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN DIEGO, May 29, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service